Table 1. Concizumab dose escalation... | American Society of Hematology

Table 1.

Concizumab dose escalation during the main + extension parts of explorer4 (HAwI, HBwI) and explorer5 (HA) according to hemophilia subtype; full analysis set

Dose escalation*	HA (n = 36)	HAwI (n = 15)	HBwI (n = 10)
None, 0.15 mg /kg only	15 (41.7)	7 (46.7)	5 (50.0)
One, 0.15 and 0.20 mg/kg	10 (27.8)	6 (40.0)	3 (30.0)
Two, 0.15, 0.20, and 0.25 mg/kg	11 (30.6)†	2 (13.3)	2 (20.0)

Dose escalation*	HA (n = 36)	HAwI (n = 15)	HBwI (n = 10)
None, 0.15 mg /kg only	15 (41.7)	7 (46.7)	5 (50.0)
One, 0.15 and 0.20 mg/kg	10 (27.8)	6 (40.0)	3 (30.0)
Two, 0.15, 0.20, and 0.25 mg/kg	11 (30.6)†	2 (13.3)	2 (20.0)

Data are presented as n (percentage of patients) with dose escalation.

†

One HA patient with 2 escalations was later de-escalated to concizumab 0.15 mg/kg, and one HA patient with 2 escalations was later de-escalated to concizumab 0.20 mg/kg before a further escalation to concizumab 0.25 mg/kg.

View Large

This Feature Is Available To Subscribers Only